Loxapine (Adasuve)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: the acute treatment of agitation associated with schizophrenia or bipolar I disorder in... (FDA)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also approved (3)
US
  • ADASUVE is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Product first approved 2012FDA label
CN
  • Acute treatment of agitation associated with schizophrenia or bipolar disorder in adults
Product first approved 2023www1.hkexnews.hk
EU
  • Rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder
Product first approved 2013EMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Bipolar Disorder
Schizophrenia
Phase 2 (3)
Schizophrenia
NCT00369577 · Alexza Pharmaceuticals, Inc.
2006-08 – 2007-01 · Schizophrenia
What this study did
Other / comorbidity
NCT00825500 · Alexza Pharmaceuticals, Inc.
2009-01 – 2009-08 · Migraine Headache
What this study did
NCT00489476 · Alexza Pharmaceuticals, Inc.
2007-06 – 2007-12 · Migraine
What this study did
Phase 1 (8)
Schizophrenia
NCT00444028 · Alexza Pharmaceuticals, Inc.
2005-09 – 2005-11 · Schizophrenia
What this study did
Other / comorbidity
NCT00889837 · Alexza Pharmaceuticals, Inc.
2009-06 – 2009-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00890175 · Alexza Pharmaceuticals, Inc.
2009-05 – 2009-08 · Asthma
What this study did
NCT00873769 · Alexza Pharmaceuticals, Inc.
2009-04 – 2009-06 · Smoking, Cigarette
What this study did
NCT00874237 · Nova Pneuma Inc.
2009-04 – 2009-06 · Thorough QT/QTc Study
What this study did
NCT00789360 · Alexza Pharmaceuticals, Inc.
2008-11 – 2009-04 · Healthy
What this study did
NCT00555412 · Alexza Pharmaceuticals, Inc.
2007-10 – 2007-12 · Volunteers on Chronic, Stable Antipsychotic Regimens
What this study did
Phase 4 (3)
Other / comorbidity
NCT02525991 · Ferrer Internacional S.A.
2016-09-08 – 2019-12-31 · Agitation
What this study did
NCT01854710 · Alexza Pharmaceuticals, Inc.
2013-05 – 2013-07 · Healthy Volunteers
What this study did
NCT01877642 · Alexza Pharmaceuticals, Inc.
2013-06 – 2013-07 · Healthy Volunteers
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, 21 of them ahead of this one.

This drug's own stage for Bipolar Disorder: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Loxapine (Adasuve): this drugPhase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.